483
Alvogen, IncFDA 483 - Alvogen, Inc - June 10, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
Alvogen, Inc. in Morristown, NJ, underwent an inspection of its corporate office, revealing a significant deficiency in its Risk Evaluation and Mitigation Strategy (REMS) program. The firm failed to maintain a required REMS Program website link on its product website, which is a critical component of its approved REMS Implementation System. This indicates a lapse in adhering to established safety and communication protocols for opioid analgesic products.
Open in Dashboard
ID · 4c5dff3f-5a91-4cfa-9d81-935cfaa13575